Literature DB >> 26346906

Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells.

L H Pugholm1,2, L R Petersen2, E K L Søndergaard1, K Varming1, R Agger2.   

Abstract

Dendritic cells (DCs) are superior in their ability to induce and control adaptive immune responses. These qualities have motivated the hypothesis that targeted delivery of antigen to DCs in vivo may be an effective way of enhancing immunization. Recent results show that antigen targeted to certain DC surface molecules may indeed induce robust immune responses. Targeting of antigen to DCs can be accomplished by the means of monoclonal antibodies. This study compared the humoral responses induced in mice by in vivo targeting of DCs using monoclonal antibodies specific for CD11c, CD36, CD205, Clec6A, Clec7A, Clec9A, Siglec-H and PDC-TREM. The results demonstrate that antigen delivery to different targets on DCs in vivo gives rise to humoral responses that differ in strength. Targeting of antigen to CD11c, CD36, CD205, Clec6A, Clec7A and PDC-TREM induced significantly stronger antibody responses compared to non-targeted isotype-matched controls. Targeting of Clec9A and Siglec-H did not lead to efficient antibody responses, which may be due to unfavourable properties of the targeting antibody, in which case, other antibodies with the same specificity might elicit a different outcome. Anti-CD11c was additionally used for elucidating the impact of the route of vaccination, and the results showed only minor differences between the antibody responses induced after immunization either s.c., i.v. or i.p. Altogether, these data show that targeting of different surface molecules on DCs result in very different antibody responses and that, even in the absence of adjuvants, strong humoral responses was induced.
© 2015 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26346906     DOI: 10.1111/sji.12387

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.

Authors:  Diana Corogeanu; Sandra S Diebold
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 2.  Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies.

Authors:  Christian H K Lehmann; Lukas Heger; Gordon F Heidkamp; Anna Baranska; Jennifer J Lühr; Alana Hoffmann; Diana Dudziak
Journal:  Vaccines (Basel)       Date:  2016-03-28

3.  Endocytosis Deficient Murine Xcl1-Fusion Vaccine Enhances Protective Antibody Responses in Mice.

Authors:  Arnar Gudjonsson; Tor Kristian Andersen; Vibeke Sundvold-Gjerstad; Bjarne Bogen; Even Fossum
Journal:  Front Immunol       Date:  2019-05-17       Impact factor: 7.561

Review 4.  Enhancing Protective Efficacy of Poultry Vaccines through Targeted Delivery of Antigens to Antigen-Presenting Cells.

Authors:  Angita Shrestha; Jean-Remy Sadeyen; Munir Iqbal
Journal:  Vaccines (Basel)       Date:  2018-11-15

5.  Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies.

Authors:  Bihua Deng; Hafizah Y Chenia; Hai Xu; Ling Li; Weiming Hong; Ruiting Li; Zijie Guo; Jibo Hou; Roshini Govinden
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

Review 6.  Targeting dendritic cells: a promising strategy to improve vaccine effectiveness.

Authors:  Christophe Macri; Claire Dumont; Angus Pr Johnston; Justine D Mintern
Journal:  Clin Transl Immunology       Date:  2016-03-18

Review 7.  Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.

Authors:  Dieke van Dinther; Dorian A Stolk; Rieneke van de Ven; Yvette van Kooyk; Tanja D de Gruijl; Joke M M den Haan
Journal:  J Leukoc Biol       Date:  2017-07-20       Impact factor: 4.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.